Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

September 17, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Cancer, COVID-19 and reconciling the Riddles

Tata Medical Center Proteomics Research Assistant Recruitment

Can Fe2+ and Mn2+ protect the ribosome under oxidative stress conditions?

Cancer, COVID-19 and reconciling the Riddles
  • BiotechToday
  • World

Cancer, COVID-19 and reconciling the Riddles

bioxone October 14, 2020October 14, 2020

Srilagna Sarkar, Amity University Kolkata

Severe acute respiratory syndrome Coronavirus 2(SARS-CoV-2) and related to the Coronavirus disease as seen has led to a novel degree of disturbance globally. Whether oncology stakeholders, its patients, families or clinicians are adjusting and conforming with the challenges caused by the convergence of the two-life threatening diseases.

Two studies by Albiges et al. and Rugge et al., in Nature Cancer, gives insight into the determinants of the result in severe COVID-19 patients with cancer.  The first studies revealed conflicting results. The early studies in 5,688 of New York City COVID-19 patients, 6% of which had Cancer and the rest were without cancer, showed unclear results in the difference between the two groups of patients. On contrary, another multi-centre study of 14 hospitals with 641 COVID-19 patients of which 105 were with cancer and the rest of the 536 patients were without cancer, matched by age, time and the site of hospitalization. Signified that the ones both with Covid-19 and cancer had a higher risk of in-hospital infection, intensive care unit (ICU) admission and invasive mechanical ventilation with observable death rates; than of those with only COVID-19.

Though the inconsistent findings from these and earlier series indicated towards the need for continued reporting and analysis of death rate and another clinical outcome of patients with both COVID-19 and cancer.

To, increase the growing evidence Albigo et al. and Rugge et al. presented their early independent study from France and Italy. Albigo et al. analyzed variables with prognostic value for clinical worsening or death in 178 COVID-19 patients with and without cancer, for 6 weeks. Reports showed an increased risk of death in patients of above 70 years of age. One of the most important findings of Albigo et al. is that the glimpse that is provided on the impact of COVID-19 on cancer strategies and posts COVID-19 assessment of cancer patients.

Rugge et al’s study showed a report from the population level view of COVID-19 and cancer patients among the residents of Venito region. This study can be considered as important as not many data have been reported directly from the community.

Hence, with the growing shreds of evidence and the effects of COVID-19 in patients with and without cancer. Population-based, clinic-epidemiological studies are important as they are better exhibitors for the general mass with cancer. 

Also read: COVID UPDATE: Decrease in daily active cases in India

Source: https://www.nature.com/articles/s43018-020-00129-w

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged cancer COVID diagnosis COVID in Cancer patients COVID-19 negative impacts of COVID-19 in cancer patients pandemic SARS-CoV-2

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Can Fe2+ and Mn2+ protect the ribosome under oxidative stress conditions?

bioxone October 14, 2020

Husna, Amity University Kolkata Protein biosynthesis is the basic need of cellular life for which it requires the systematic functioning of the translational machinery. At the centre of this machinery, the ribosome is present which is a ribonucleoprotein complex and depends heavily on Mg2+ for its structure.  Recent experimental studies indicate that other metal cations […]

oxidative stress

Related Post

  • BiotechToday
  • World

HIV vaccine trials re-initiated at Oxford after 40 years

BioTech Today July 10, 2021July 10, 2021

Sneha Singhal, Jaypee Institute of information technology, Noida Oxford University researchers have announced that volunteers have received the first HIV (Human immunodeficiency) vaccination to find an effective cure for the virus. It has been 40 years since an effective HIV vaccine has been discovered. Trials are underway to develop an effective vaccine against HIV. The […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A genotypic variant rs2666433 of microRNA-34a, as a novel biomarker and future for genetic risk profiling in colorectal cancer

bioxone October 12, 2020October 11, 2020

Chitra Roy, University of Calcutta MicroRNA is a non-protein-coding RNA molecule about 18-22 nucleotides long which post-transcriptionally regulates various gene expression through genetic and epigenetic mechanisms. They have several target genes on mRNA and the complementarity of microRNA-mRNA is the basis of gene silencing either by inhibiting the translation process or by directly degrading the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

ENGINEERED ONCOLYTIC ADENOVIRUS TO TREAT METASTATIC CANCER

bioxone December 2, 2020December 2, 2020

Husna, Amity University Kolkata Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy